Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors | MicrobiomeTrials← Back to trialsNCT02717156
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2016-11-21Est. Completion: 2027-12-31
Enrollment target: 70 participants Locations- City of Hope, Duarte, California, United States
- LAC+USC Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- USC Norris Oncology/Hematology - Newport Beach, Newport Beach, California, United States
- UC Davis Comprehensive Cancer Center, Sacramento, California, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
- Levine Cancer Institute-Carolinas Medical Center, Charlotte, North Carolina, United States
- University of Virginia Cancer Center, Charlottesville, Virginia, United States
Other microbiome trials you might be interested in
Muscle-Invasive Bladder Cancer (MIBC)Urinary Bladder Cancer
For patients with HER2-expressing muscle-invasive bladder cancer (MIBC), current neoadjuvant therapies dominated by plat…
Multiple LocationsEst. completion Jun 5, 2028
Urothelial CancerUrinary Bladder Neoplasms
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder pre…
Santa Barbara, United StatesEst. completion Mar 31, 2030